Tasimelteon
Brand name: Hetlioz
Rank #431 of 500 drugs by total cost
$19.3M
Total Cost
763
Total Claims
$19.3M
Total Cost
57
Prescribers
$25K
Cost per Claim
0
Beneficiaries
777
30-Day Fills
$338K
Avg Cost/Provider
13
Avg Claims/Provider
About Tasimelteon
Tasimelteon (sold as Hetlioz) was prescribed 763 times by 57 Medicare Part D providers in 2023, costing the program $19.3M. At $25K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 428 | Sumatriptan Succinate (Sumatriptan Succinate) | $19.4M | 555,011 |
| 429 | Darbepoetin Alfa In Polysorbat (Aranesp) | $19.3M | 6,889 |
| 430 | Ondansetron Hcl (Ondansetron Hcl) | $19.3M | 1,255,548 |
| 431 | Tasimelteon (Hetlioz) | $19.3M | 763 |
| 432 | Isavuconazonium Sulfate (Cresemba) | $19.2M | 3,050 |
| 433 | Paroxetine Hcl (Paroxetine Hcl) | $19.2M | 1,226,222 |
| 434 | Naloxone Hcl (Naloxone Hcl) | $19.0M | 232,875 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology